SAN FRANCISCO–(BUSINESS WIRE)–January 12, 2026–
Owkin, an AI company with a mission to solve the complexities of biology, today announced that its interoperable Pathology Explorer AI agent will be included in Anthropic’s launch of Claude for Healthcare and Life Sciences (HCLS). This is the first time that a highly specialized, world-leading biological agent, trained primarily on multimodal patient data, has been made accessible to a broad audience of medical and life sciences professionals through a Model Context Protocol (MCP).
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20260112836381/en/
Owkin’s specialized biological AI agent Pathology Explorer launches with Anthropic’s Claude for healthcare and life sciences.
The partnership enables Owkin’s advanced pathology analysis capabilities to be seamlessly integrated into Claude’s AI platform, allowing healthcare institutions, pharmaceutical companies, and research institutions to access advanced biological intelligence within Claude workflows without requiring system overhauls or proprietary process changes.
“I believe this drug interoperability is the future of biopharmaceutical discovery,” said Thomas Clozel, MD, CEO and co-founder of Owkin. “By making our best-in-class agents, trained on patient data from the world’s leading hospitals, accessible through portals like Claude for HCLS, we are empowering the largest healthcare organizations to accelerate research in ways never before possible. This means putting patient data first when training AI and making that intelligence widely available to cure diseases faster.”
Pathology Explorer is part of Owkin’s K Pro community of biological agents. This agent identifies and localizes cell and tissue types, enabling spatially aware analysis of patient tissue images. This agent allows users to analyze tumors and their microenvironment and study inflammatory patterns. Pathology Explorer allows you to extract biomarkers from digitized pathology images to generate and test hypotheses through cohort-level survival analysis. This is a key capability for accelerating drug discovery, clinical trial design, and the development of digital diagnostic tools. The agent leverages a unique, best-in-class AI model trained on patient histopathology data from Owkin’s network of more than 800 hospitals in 104 medical centers to deliver highly accurate analysis.
Owkin MCP integration allows seamless access
Owkin has developed an industry standard MCP encoding specifically designed to allow our proprietary K Pro agents to seamlessly integrate with Claude’s interface. Pathology Explorer is the first agent offered for external integration from Owkin’s interoperable biological agent AI infrastructure, demonstrating the company’s commitment to building an open, API-first infrastructure that serves as a universal foundation for advancing drug development.
Claude for Healthcare and Life Sciences is designed to accelerate preclinical research and development (including bioinformatics, protocol development, and literature synthesis), streamline clinical trial operations and data management, and support regulatory operations and submission preparation. Owkin’s Pathology Explorer integration extends these capabilities by enabling deep biological inference specifically trained on real patient data.
This is the third in a series of major announcements from Owkin, including a strategic partnership with NVIDIA to power Owkin’s biological agent infrastructure, Owkin’s new interoperable agent infrastructure for biopharmaceuticals, and OwkinZero, Owkin’s biological large-scale inference model.
About Orkin
Owkin is an AI company with $300 million in funding on a mission to solve the complexities of biology. We are building the first biologically artificial super intelligence (BASI) by combining powerful biological large-scale inference models, multimodal patient data, and agent software. At the heart of the system is Owkin K, an AI co-pilot, and OwkinZero, Owkin’s large-scale biological reasoning model, used by researchers, clinicians, and drug developers to better understand biology, test scientific hypotheses, and deliver better diagnoses and treatments faster. Owkin has exclusive access to 10 years of combined patient data from more than 800 hospitals and partners with 8 out of 10 major pharmaceutical companies. For more information, please visit www.owkin.com.
Owkin Media Kit: https://www.owkin.com/press-kit
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112836381/en/
Contact: Press Contact:
– USA: Erica Seidenberg -erica@hotTomato.net
– UK: Ali Jennings -alistair.jennings@owkin.com
– EU: Malika Labou -malika.labou-ext@owkin.com
Keywords: California Europe United States North America
Industry Keywords: Research Technology Health Technology Software Biotechnology Hardware Health Data Management Science Artificial Intelligence
Source: Orkin
Copyright Business Wire 2026.
Pub: 01/12/2026 12:00 PM/Disc: 01/12/2026 12:00 PM
http://www.businesswire.com/news/home/20260112836381/ja
Copyright Business Wire 2026.
